Shares Magazine
118.00p+0.00 (+0.00%)19 Nov 2024, 14:29
Jump to:
Diaceutics PLC Fundamentals
| Company Name | Diaceutics PLC | Last Updated | 2024-11-19 |
|---|---|---|---|
| Industry | Diagnostics & Research | Sector | Healthcare |
| Shares in Issue | 84.468 m | Market Cap | £99.67 m |
| PE Ratio | 129.87 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.02 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.0250 | Debt Equity Ratio | 0.0254 |
| Asset Equity Ratio | 1.1726 | Cash Equity Ratio | 0.4323 |
| Quick Ratio | 4.5792 | Current Ratio | 4.85 |
| Price To Book Value | 2.5727 | ROCE | 0 |
Diaceutics PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Diaceutics PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|---|---|---|
| Tangible Assets | £1.90 m | £2.09 m | £2.13 m |
| Intangible Assets | £15.26 m | £15.22 m | £12.82 m |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | £18.30 m | £17.36 m | £14.95 m |
| Stocks | 0 | 0 | 0 |
| Debtors | £10.13 m | £8.58 m | £7.15 m |
| Cash & Equivalents | £16.67 m | £19.84 m | £19.68 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £46.34 m | £48.26 m | £45.01 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|---|---|---|
| Creditors within 1 year | £4.38 m | £3.75 m | £2.63 m |
| Creditors after 1 year | £1.18 m | £1.99 m | £1.73 m |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £5.56 m | £5.74 m | £4.36 m |
| Net assets | £40.79 m | £42.51 m | £40.65 m |
| Equity | 2023 | 2022 | 2021 |
|---|---|---|---|
| Called up share capital | £169,000.00 | £169,000.00 | £168,000.00 |
| Share Premium | £37.13 m | £37.13 m | £36.86 m |
| Profit / Loss | -£2.44 m | £564,000.00 | £462,000.00 |
| Other Equity | £40.79 m | £42.51 m | £40.65 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £40.79 m | £42.51 m | £40.65 m |
| Ratios | 2023 | 2022 | 2021 |
|---|---|---|---|
| Debt Ratio | £0.03 | £0.03 | £0.03 |
| Debt-to-Equity | £0.03 | £0.03 | £0.03 |
| Assets / Equity | 1.1726 | 1.1726 | 1.1726 |
| Cash / Equity | 0.4323 | 0.4323 | 0.4323 |
| EPS | -£0.02 | £0.01 | £0.01 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|---|---|---|
| Cash from operating activities | £1.31 m | £5.10 m | £570,000.00 |
| Cashflow before financing | £1.07 m | £4.91 m | £300,000.00 |
| Increase in Cash | -£3.14 m | £146,000.00 | -£5.30 m |
| Income | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | £23.70 m | £19.50 m | £13.94 m |
| Cost of sales | £3.99 m | £2.76 m | £1.71 m |
| Gross Profit | £19.71 m | £16.74 m | £12.23 m |
| Operating Profit | -£3.02 m | £575,000.00 | £550,000.00 |
| Pre-Tax profit | -£2.44 m | £564,000.00 | £462,000.00 |
Diaceutics PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides the pharma and biotech companies with an end-to-end commercialization solution for the launch of precision medicine, enabled by DXRX The Diagnostic Network. DXRX is the diagnostic commercialization platform designed specifically for precision medicine, integrating multiple pipelines of real-world, real-time diagnostic testing data from a network of labs. These solutions are helping the pharma companies commercialize their precision medicines, enhance their return on investment and ultimately improve patients' lives. |
| Latest Interim Date | 17 Sep 2024 |
| Latest Fiscal Year End Date | 21 May 2024 |
Diaceutics PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2024-05-29 | Mr. Michael Wort | Non-Executive Director |
| 2024-05-29 | Mr. Charles Hindson | Non-Executive Director |
| 2024-05-23 | Mr. Graham Douglas Paterson | Non-Executive Director,Senior Independent Director |
| 2024-10-01 | Ms. Deborah Lee Davis | Non-Executive Director,Chairman |
| 2020-12-22 | Ms. Julie Goonewardene Wallin | Non-Executive Director,Chairman |
| 2024-05-29 | Mr. Peter Keeling | Non-Executive Director,Chairman |
| 2024-10-25 | Mr. Ryan Keeling | Executive Director,Chief Executive Officer |
| 2022-03-18 | Mr. Philip White FCA | Executive Director,Chief Financial Officer |
| 2024-10-30 | Mr. Nicholas Stewart Roberts | Executive Director,Chief Financial Officer |
| 2024-10-30 | Mr. Jordan Russell Clark | Executive Director,Chief Data Officer |
Diaceutics PLC Contact Details
| Company Name | Diaceutics PLC |
|---|---|
| Address | 55-59 Adelaide Street, Titanic Suites, Enterprise House, Antrim, BT2 8FE |
| Telephone | |
| Website | https://www.diaceutics.com |
Diaceutics PLC Advisors
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Vesuvius PLC | 399.00 | 7.98 |
| Bodycote PLC | 616.00 | 7.13 |
| Petershill Partners PLC | 253.50 | 5.19 |
| Hochschild Mining PLC | 229.00 | 5.77 |
| Imperial Brands PLC | 2,475.00 | 3.08 |
| Bt Group PLC | 148.35 | 2.49 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Diploma PLC | 4,160.00 | -8.29 |
| Burberry Group PLC | 857.80 | -5.24 |
| Big Yellow Group PLC | 1,102.00 | -4.51 |
| Senior PLC | 142.80 | -3.25 |
| Aston Martin Lagonda Global Holdings PLC | 106.40 | -3.36 |
| Close Brothers Group PLC | 201.40 | -2.42 |